Perioperative Nivolumab Does Not Sacrifice QoL in NSCLC



Perioperative nivolumab in eligible patients with resectable non-small cell lung cancer offers improved survival outcomes and preserves quality of life, new data show.
Medscape Medical News



Source link : https://www.medscape.com/viewarticle/perioperative-nivolumab-does-not-sacrifice-qol-nsclc-2025a1000nl9?src=rss

Author :

Publish date : 2025-09-07 15:31:00

Copyright for syndicated content belongs to the linked Source.
Exit mobile version